Volume 4, Issue 12
Editorialp. 1057–105
How can we effectively identify and report clinical research misconduct?
Author(s): Glenda Guest
Editorialp. 1061–106
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Author(s): Jie Huang
Research Articlep. 1065–108
An evaluation of recruitment methods utilized for a clinical trial with periodontal and diabetes enrollment criteria: the Diabetes and Periodontal Therapy Trial
Author(s): Elinor R Schoenfeld, Leslie Hyman, Leslie Long Simpson, Bryan Michalowicz, Michael Reddy, Marie Gelato, Wei Hou, Steven P Engebretson, Catherine Hytner, Pat Lenton & the DPTT Study Group
Clinical Trail Methodologyp. 1083–109
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Author(s): Timothy R Wilson & Mark R Lackner
Clinical Trail Outcomesp. 1095–111
Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials
Author(s): Marc Miravitlles, Kai-Michael Beeh & Pablo Altman
Clinical Trail Outcomesp. 1113–112
Therapeutic targeting of tumor angiogenesis: how far have we come?
Author(s): Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomesp. 1123–113
The phosphatidyl-inositol 3-kinase/Akt/ mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer
Author(s): Saad A Khan & Julie E Bauman
Clinical Trail Outcomesp. 1139–115
Overview on clinical trials in Waldenstroms macroglobulinemia
Author(s): Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
